09:12 AM EDT, 08/28/2024 (MT Newswires) -- Atossa Therapeutics ( ATOS ) said Wednesday that the US Patent and Trademark Office has granted it a new patent covering compositions of endoxifen and an enteric-coating material in which at least 90% of the endoxifen is (Z)-endoxifen.

The breast cancer-focused biopharmaceutical company said the patent also covers methods of administering those compositions to patients.

The company said (Z)-endoxifen has demonstrated effectiveness in patients with tumor resistance to other hormonal treatments.

Price: 1.3600, Change: +0.01, Percent Change: +0.74